JAK2 and myeloproliferative disorder: Compounds 1, 2, and 7 also inhibited viability of MPN model cell lines HEL and SET-2 (Table 2), both of which express JAK2 V617F (homozygous in HEL, heterozygous in SET-2), and murine pro-B cells Ba/F3 carrying either hJAK2 wildtype or V617F (Supplementary Table S6) at submicromolar-micromolar range.